Wed, Oct 1, 2014, 7:27 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

labois4u 8 posts  |  Last Activity: Jul 24, 2014 9:10 AM Member since: Jun 28, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Twenty-five-year outbreak of Pseudomonas aeruginosa infecting individuals with cystic fibrosis: identification of the prairie epidemic strain.
    Parkins MD1, Glezerson BA, Sibley CD, Sibley KA, Duong J, Purighalla S, Mody CH, Workentine ML, Storey DG, Surette MG, Rabin HR.
    Author information
    Abstract

    Transmissible strains of Pseudomonas aeruginosa have been described for cystic fibrosis (CF) and may be associated with a worse prognosis. Using a comprehensive strain biobank spanning 3 decades, we sought to determine the prevalence and stability of chronic P. aeruginosa infection in an adult population. P. aeruginosa isolates from sputum samples collected at initial enrollment in our adult clinic and at the most recent clinic visit were examined by a combination of pulsed-field gel electrophoresis and multilocus sequence typing and compared against a collection of established transmissible and local non-CF bronchiectasis (nCFB) isolates. A total of 372 isolates from 107 patients, spanning 674 patient-years, including 66 patients with matched isolates from initial and final encounters, were screened. A novel clone with increased antibacterial resistance, termed the prairie epidemic strain (PES), was found in 29% (31/107 patients) of chronically infected patients referred from multiple prairie-based CF centers. This isolate was not found in those diagnosed with CF as adults or in a control population with nCFB. While 90% (60/66 patients) of patients had stable infection over a mean of 10.8 years, five patients experienced strain displacement of unique isolates, with PES occurring within 2 years of transitioning to adult care. PES has been present in our cohort since at least 1987, is unique to CF, generally establishes chronic infection during childhood, and has been found in patients at the time of transition of patients from multiple prairie-based CF clinics, suggesting broad endemicity. Studies are under way to evaluate the clinical implications of PES infection.

    Sentiment: Strong Buy

  • labois4u labois4u Jul 14, 2014 11:19 AM Flag

    Funny! Didn't Shire bought Iplex earlier?

    Company Insmed Inc.
    Description Complex of insulin-like growth factor-1 (IGF-1) and its principal binding protein, IGF binding protein 3 (IGFBP3)
    Molecular Target Insulin-like growth factor-1 (IGF-1) receptor (IGF1R) (CD221) ; Insulin-like growth factor (IGF) binding protein 3 (IGFBP3)
    Mechanism of Action Insulin-like growth factor-1 (IGF-1) receptor agonist
    Therapeutic Modality Biologic: Protein
    Latest Stage of Development Phase II
    Standard Indication Retinopathy of prematurity
    Indication Details Treat retinopathy of prematurity (ROP)
    Regulatory Designation

    Partner Shire plc

    Sentiment: Strong Buy

  • Reply to

    Just a list...Or not?

    by labois4u Jul 10, 2014 4:36 PM
    labois4u labois4u Jul 10, 2014 4:42 PM Flag

    Mirna Therapeutics Inc. CFO
    NephroGenex Ceo
    Novartis Executive Director of Business Development
    Novartis Executive Director of Business Development and Alliance Management
    Novo Nordisk Director of Biopharm Sourcing
    Nuvo Research Chairman and Co-Chief Executive Officer
    Oncothyreon Inc. Vice President of Business Development
    ONO Pharma USA Senior Director
    Pfizer Inc. Vice President of Worldwide Business Development
    Pharmazz Chairman
    Piramal Pharma Inc Business Development Manager
    Prometheon Pharma LLC Director Business Development
    Prosensa Therapeutics Chief Business Officer
    Recordati Rare Diseases Director of Business Development
    Regeneron Pharmaceuticals, Inc. Director of Business Development
    Resverlogix Corp. Senior Vp Of Business & Market Development
    RuiYi President and Chief Executive Officer
    Sanofi Vice President, BD Licensing & Structured Investments, Strategy & Business
    Sanofi-Aventis Vice President of Business Development North American Pharmaceuticals
    SR-one Business Development
    Syapse President and Founder
    Takeda Ventures President and CEO
    The University of Pennsylvania Director, Alliance Management, Translational Research Program
    Tocagen Inc Chief Executive Officer and President
    UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences Director of Industrial Relations and Development
    Upsher-Smith Laboratories Director - Business Development
    Upsher-Smith Laboratories Associate Vice President of Partner Relations
    Zosano Pharma Director Business Development
    Zosano Pharma VP Corporate Developmen

    Sentiment: Strong Buy

  • Company Job Title
    AbbVie Director – External Research
    Allergan, Inc. Vice President of Business Development
    Altiris Therapeutics, Inc. President & Ceo
    Ash Stevens Inc. Director of Business Development
    Ash Stevens Inc. Vice President of Business Development
    AstraZeneca Director of Business Development and Strategic Partnering
    AstraZeneca Vice-President Strategic Partnering and Business Development, CNS & Pain
    Avalon Ventures Managing Director
    Biogen Idec Vice President of Business Development
    BMS Vice President, Business Development
    Boehringer Ingelheim Global Head Of Business Development and Licensing Respiratory
    Celgene Executive Director, Business Development
    Civitas Therapeutics Business Development Officer
    Cornerstone Therapeutics Sr. Director, Business Development
    Cornerstone Therapeutics Vice President of Strategy and Business Developemt
    CSL Behring VP Business Development
    Cubist Pharmaceuticals Senior Director of Corporate Development
    Daiichi Sankyo Svp, Esa
    Dyax Corp. Executive Vice President of Corporate Development and General Counsel
    Elcelyx Therapeutics Senior Vice President of Corporate and Business Development
    Epirus Biopharmaceuticals SVP Business Development
    Epirus Biopharmaceuticals Chief Business Officer
    Galderma Laboratories, L.P Associate Director - US Business Dev.
    Gilead Sciences, Inc. Senior Director of Alliance Management and Corporate Development
    Good Start Genetics Inc. Head, Corporate Development
    HealthCare Royalty Partners Principal
    HoneyLab Ltd Ceo
    Insmed CEO & President Insmed
    Isis Pharmaceuticals, Inc. Director, Business Development
    Janssen R&D US Head of Janssen Labs
    Juventas Therapeutics Vice President of Business Development
    Kaiser Permanente Assistant Medical Director Chief Medical Information Officer
    MacroGenics Inc. Vice President, Business Development
    Mallinckrodt VP Business Development & Licensing
    Mallinckrodt Director of Business Development
    Merkle Inc Director of Worldwide Licensing
    Milestone Pharmaceuticals Chief Executive Officer

    Sentiment: Strong Buy

  • This is great!...in EU we file for both ndications!!!...
    Slide 16

    Sentiment: Strong Buy

  • Reply to

    OT May the 4th.....

    by insmhistorian May 4, 2014 12:25 PM
    labois4u labois4u May 4, 2014 3:59 PM Flag

    ...und feier the 5th!

    Sentiment: Strong Buy

  • Reply to

    So Japan becomes a strong possibilty

    by justarook04 Apr 24, 2014 8:22 AM
    labois4u labois4u Apr 28, 2014 1:17 AM Flag

    Schimmer is good!

    Sentiment: Strong Buy

  • Reply to

    NTM revenue = $3.5 billion (110,000 cases * $35,000)

    by labois4u Nov 19, 2013 10:16 AM
    labois4u labois4u Apr 27, 2014 2:32 PM Flag

    Agree!

    Sentiment: Strong Buy

INSM
12.57-0.48(-3.68%)Oct 1 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.